MX2016013575A - Composicion para prevenir o tratar enfermedades del higado graso. - Google Patents

Composicion para prevenir o tratar enfermedades del higado graso.

Info

Publication number
MX2016013575A
MX2016013575A MX2016013575A MX2016013575A MX2016013575A MX 2016013575 A MX2016013575 A MX 2016013575A MX 2016013575 A MX2016013575 A MX 2016013575A MX 2016013575 A MX2016013575 A MX 2016013575A MX 2016013575 A MX2016013575 A MX 2016013575A
Authority
MX
Mexico
Prior art keywords
preventing
fatty liver
liver diseases
composition
treating fatty
Prior art date
Application number
MX2016013575A
Other languages
English (en)
Other versions
MX369571B (es
Inventor
Ha Kim Soon
Jin Kim Hyoung
Sul Park Heui
Hyun Ahn Seo
Ho Shong Min
Kyun Chung Hyo
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2016013575A publication Critical patent/MX2016013575A/es
Publication of MX369571B publication Critical patent/MX369571B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a una composición farmacéutica para prevenir o tratar enfermedades del hígado graso, que contiene (tetrahidropiran-4-il)-[2-fenil-5-(1,1-dioxo-tiomorfolin- 4-il)metil-1H-indol-7-il]amina o una sal farmacéuticamente aceptable de la misma como ingredientes activos. La (tetrahidropiran-4-il)-[2-fenil-5-(1,1-dioxo-tiomorfolin-4-il)met il-1H-indol-7-il] amina o una sal farmacéuticamente aceptable de la misma, de acuerdo con la presente invención, puede inhibir de manera efectiva el hígado graso, hepatitis y fibrosis del higado, y puede ser útil para prevenir o tratar NAFLD, y en particular, NASH.
MX2016013575A 2014-04-18 2015-04-17 Composicion para prevenir o tratar enfermedades del higado graso. MX369571B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140046904 2014-04-18
PCT/KR2015/003869 WO2015160213A1 (ko) 2014-04-18 2015-04-17 지방간 질환의 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
MX2016013575A true MX2016013575A (es) 2017-06-08
MX369571B MX369571B (es) 2019-11-12

Family

ID=54324325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013575A MX369571B (es) 2014-04-18 2015-04-17 Composicion para prevenir o tratar enfermedades del higado graso.

Country Status (10)

Country Link
US (1) US9814726B2 (es)
EP (1) EP3132795B1 (es)
JP (1) JP6490097B2 (es)
KR (1) KR102006247B1 (es)
CN (2) CN106659722A (es)
BR (1) BR112016024020A8 (es)
ES (1) ES2851006T3 (es)
MX (1) MX369571B (es)
RU (1) RU2664696C2 (es)
WO (1) WO2015160213A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019111048A1 (en) * 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
WO2021107029A1 (ja) * 2019-11-26 2021-06-03 田辺三菱製薬株式会社 ヒトの非アルコール性脂肪肝炎の予防薬または治療薬
EP4136971A4 (en) * 2020-03-31 2023-11-22 Lg Chem, Ltd. ISLAND TRANSPLANT PROTECTION COMPOSITION
WO2022039506A1 (ko) 2020-08-19 2022-02-24 주식회사 미토이뮨테라퓨틱스 Ｍabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
CN114470217B (zh) * 2020-11-24 2023-06-20 深圳微芯生物科技股份有限公司 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物
KR20220141251A (ko) 2021-04-12 2022-10-19 주식회사 미토이뮨테라퓨틱스 5-[(1,1-디옥시도-4-티오몰포리닐)메틸]-2-페닐-n-(테트라하이드로-2h-피란-4-일)-1h-인돌-7-아민의 신규 결정형
US20240199598A1 (en) 2021-04-12 2024-06-20 Mitoimmune Therapeutics Inc. Sulfate of 5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-n-(tetrahydro-2h-pyran-4-yl)-1h-indole-7-amine, and novel crystal form thereof
CN117794917A (zh) 2021-08-02 2024-03-29 水疗免疫疗法有限公司 新型吲哚衍生物、包含其的药物组合物及其用途
KR20230019797A (ko) 2021-08-02 2023-02-09 주식회사 미토이뮨테라퓨틱스 인돌 유도체, 이의 제조방법 및 약학적 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308839B1 (en) * 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
CN101801965B (zh) * 2007-08-17 2014-07-30 株式会社Lg生命科学 作为细胞坏死抑制剂的吲哚化合物
JP5583022B2 (ja) * 2007-11-30 2014-09-03 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法
US20100291533A1 (en) * 2008-01-04 2010-11-18 Soon Ha Kim Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect
DK2460403T3 (da) * 2009-07-31 2019-08-19 Smc Global Asset Inc Steatohepatitis lever cancer model mus
TW201119651A (en) * 2009-10-26 2011-06-16 Lg Life Sciences Ltd Pharmaceutical composition comprising indole compound
KR101404151B1 (ko) * 2011-11-25 2014-06-05 가톨릭대학교 산학협력단 안과 질환의 예방 및 치료용 약학 조성물
KR20130087283A (ko) * 2012-01-27 2013-08-06 재단법인 의약바이오컨버젼스연구단 인돌 및 인다졸 유도체를 유효성분으로 포함하는 암 전이 억제용 조성물
KR101413207B1 (ko) * 2012-06-14 2014-07-01 부산대학교 산학협력단 염증성 질환의 예방 또는 치료용 약학 조성물 및 건강기능식품

Also Published As

Publication number Publication date
WO2015160213A1 (ko) 2015-10-22
JP2017511373A (ja) 2017-04-20
EP3132795A1 (en) 2017-02-22
JP6490097B2 (ja) 2019-03-27
BR112016024020A8 (pt) 2021-07-20
US9814726B2 (en) 2017-11-14
MX369571B (es) 2019-11-12
RU2016145066A (ru) 2018-05-20
CN113967215A (zh) 2022-01-25
KR102006247B1 (ko) 2019-08-01
RU2016145066A3 (es) 2018-05-20
CN106659722A (zh) 2017-05-10
BR112016024020A2 (pt) 2017-08-15
US20170035776A1 (en) 2017-02-09
RU2664696C2 (ru) 2018-08-21
EP3132795B1 (en) 2020-10-21
EP3132795A4 (en) 2017-11-29
ES2851006T3 (es) 2021-09-02
KR20150120877A (ko) 2015-10-28

Similar Documents

Publication Publication Date Title
MX369571B (es) Composicion para prevenir o tratar enfermedades del higado graso.
MA40028A (fr) Compositions détergentes en doses unitaires
MX2022001292A (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
MY189913A (en) Preparation containing tetracyclic compound at high dose
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
WO2014106846A3 (en) Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
PE20140255A1 (es) Tableta dispersable en forma oral
SG10201806854XA (en) Compositions comprising 15-ohepa and methods of using the same
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
WO2014153009A3 (en) Thiosaccharide mucolytic agents
EP3020405A4 (en) Composition for preventing and treating liver fibrosis or liver cirrhosis,containing, as active ingredient, mesenchymal stem cells derived from human embryonic stem cells
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
MX2015006223A (es) Composiciones farmaceuticas de inhibidores cetp.
MY168778A (en) Oligonucleotide chelate complex-polypeptide compositions and methods
WO2018088813A3 (ko) Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
WO2016108572A3 (ko) 콜레스테롤 관련 질환의 예방 및 치료용 조성물
MX2017006476A (es) Terapia de combinacion efectiva contra microorganismos, que incluye microorganismos resistentes a farmacos.
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
EP2594268A4 (en) ANGIOGENIC INHIBITORY COMPOSITION WITH MACROLACTIN A AND A DERIVATIVELY AS ACTIVE SUBSTANCES
PH12016501448A1 (en) Antifungal composition
WO2015200768A3 (en) Pharmacologic treatments of menière's disease

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: LG CHEM, LTD.

FG Grant or registration